Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #218134 on Biotech Values
DewDiligence
11/26/18 10:56 AM
#222474 RE: ghmm #218134
PDS Biotechnology is developing PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers. PDS Biotechnology plans to initiate multiple Phase 2/3 clinical trials for PDS0101 in HPV-associated cancers. …immediately following the merger, the former PDS security holders will own approximately 70% of the combined company and existing Edge security holders will own approximately 30% of the combined company… …the combined company’s common stock is expected to continue to trade on NASDAQ under a new ticker symbol to be announced at a later date…